Clinical Trials Browser

Phase 1/2 × N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide × Clear all

NCT04651127 2026-03-10

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Phase 1/2 Terminated

Uterine Cervical Neoplasms

NCT07339527 2026-01-14

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT07093710 2025-12-31

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, T-Cell, Peripheral

NCT06421948 2025-12-05

Linperlisib Combined With Chidamide in Patients With PTCL

Phase 1/2 Recruiting

Lymphoma, T-Cell, Peripheral

NCT05270200 2025-09-25

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

Phase 1/2 Not yet recruiting

Infections, Epstein-Barr Virus Infections

NCT06757387 2025-01-03

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT05370547 2024-03-06

Chidamide Bridging for CAR-T Therapy

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin

NCT05186012 2024-01-23

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin

NCT05464173 2024-01-22

CINDERELLA

Phase 1/2 Unknown

Breast Neoplasms

NCT06087419 2023-11-02

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06037239 2023-09-14

Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study

Phase 1/2 Unknown

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT05335473 2023-04-06

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Phase 1/2 Unknown

HR Positive HER2 Negative Advanced Breast Cancer

NCT05747313 2023-02-28

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT05682755 2023-01-12

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT05527275 2022-09-02

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 1/2 Unknown

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05320640 2022-04-11

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin

NCT03974243 2022-03-09

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

NCT04553393 2020-12-04

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Phase 1/2 Unknown

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

NCT04337606 2020-04-07

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin